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DOI 10.1016/j.chembiol.2010.09.011SUMMARY treatment, extending the effective lifespan of the drug. The largeClostridium difficile is a leading cause of nosocomial
infections. The major virulence factors of this path-
ogen are the multi-domain toxins TcdA and TcdB.
These toxins contain a cysteine protease domain
(CPD) that autoproteolytically releases a cytotoxic
effector domain upon binding intracellular inositol
hexakisphosphate. Currently, there are no known
inhibitors of this protease. Here, we describe the
rational design of covalent small molecule inhibitors
of TcdB CPD. We identified compounds that inacti-
vate TcdB holotoxin function in cells and solved the
structure of inhibitor-bound protease to 2.0 A˚. This
structure reveals the molecular basis of CPD
substrate recognition and informed the synthesis of
activity-based probes for this enzyme. The inhibitors
presentedwill guide the development of therapeutics
targeting C. difficile, and the probes will serve as
tools for studying the unique activation mechanism
of bacterial toxin CPDs.
INTRODUCTION
The Gram-positive anaerobic bacterium Clostridium difficile is
a major cause of hospital-acquired diarrhea and the severe
gastrointestinal illness pseudomembranous colitis (Kelly and La-
Mont, 2008; Rupnik et al., 2009). Although infection rates have
risen dramatically in the last decade, there is currently a lack of
therapeutics to treat C. difficile infection (Halsey, 2008; Kelly
and LaMont, 2008). This is in large part due to the organism’s
resistance to most classes of antibiotics. A viable strategy for
combating C. difficile and other prominent bacterial pathogens
is to target virulence factors instead of essential enzymes (Clat-
worthy et al., 2007; Puri and Bogyo, 2009). This method limits the
selective pressure on the organism to develop resistance toChemistry & Biology 17, 1201–121glucosylating toxins TcdA and TcdB are ideal targets for this
approach because they are the primary virulence factors of
C. difficile (Genth et al., 2008; Jank and Aktories, 2008). TcdB in
particular has been shown to be critical for virulence and is found
in all clinical isolates (Lyras et al., 2009; Rupnik et al., 2009).
Both TcdA and TcdB cause cell death through an orchestrated
sequence of events (Jank and Aktories, 2008). These multi-
domain toxin proteins first enter cells by triggering receptor-
mediated endocytosis (Frisch et al., 2003; Rolfe and Song,
1993); acidification of toxin-containing endosomal compart-
ments subsequently initiates translocation of the N-terminal
cytotoxic glucosyltransferase domain and presumably the
cysteine protease domain (CPD) into the cytosol (Just et al.,
1995; Pfeifer et al., 2003; Qa’Dan et al., 2000). The CPD is acti-
vated by the eukaryotic-specific small molecule inositol hexaki-
sphosphate (InsP6) (Egerer et al., 2007; Reineke et al., 2007). This
activation catalyzes the autoproteolytic release of the toxin’s
cytotoxic glucosyltransferase domain from the endosomal
membrane (Egerer et al., 2007; Pfeifer et al., 2003). The liberated
effector domain then monoglucosylates small Rho family
GTPases (Just et al., 1995), resulting in loss of cell-cell junctions
and ultimately cell death (Genth et al., 2008; Gerhard et al., 2008;
Qa’Dan et al., 2002).
CPD-mediated autoprocessing of TcdB is a critical step during
target cell intoxication. Genetic inactivation of the CPD has been
shown to reduce the overall function of TcdB in target cells
(Egerer et al., 2007). A homologous CPD also autoproteolytically
regulates the Multifunctional Autoprocessing RTX (MARTX)
toxins (Prochazkova et al., 2009; Sheahan et al., 2007; Shen
et al., 2009), an otherwise unrelated family of toxins produced
by Gram-negative bacteria (Satchell, 2007). Structural analyses
of the CPD of both families of toxins have demonstrated that
the protease is allosterically regulated by the small molecule
InsP6 (Lupardus et al., 2008; Prochazkova et al., 2009; Pruitt
et al., 2009). These analyses have also revealed that the CPD
is a clan CD protease whose closest known structural homolog
is human caspase-7 (Lupardus et al., 2008). Despite their dispa-
rate mechanism of activation, V. cholerae MARTX CPD exhibits1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1201
Figure 1. Chemical Inhibition of TcdB CPD
(A) MARTXVc CPD inhibitors Cbz-EAL-AOMK and Cbz-EAaL-EP, which contain the AOMK and aza-Leu epoxide electrophilic warheads, respectively.
(B) Gel-based TcdB(1-804) autocleavage assay. Inhibitor concentrations were titrated, and the resulting blockade of recombinant toxin autocleavage was as-
sessed by SDS-PAGE (left). The relative cleavage amounts were then quantified and globally fit to determine observed IC50 values for each compound (right).
Data represent the mean of three experiments ± standard deviation. See also Figure S1.
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Inhibitors of Clostridium difficile toxin TcdBsimilarities in substrate recognition to the caspases (Shen et al.,
2009), except that the CPD cleaves exclusively after a leucine
instead of an aspartate residue. In contrast the molecular details
of TcdB CPD substrate recognition remain uncharacterized.
In this study we used a combination of chemical synthesis and
structural analyses to probe the substrate recognition and inhib-
itor sensitivity of TcdB CPD. By screening a focused library of
substrate-based CPD inhibitors, we identified several com-
pounds capable of blocking holotoxin function in cell culture.
We also solved the structure of TcdB CPD bound to one of these
inhibitors. Combined with the structure-activity relationship
(SAR) series derived from our inhibitor analyses, these results
provide a foundation for the development of therapeutics target-
ing this important virulence factor. We further used this informa-
tion to develop activity-based probes (ABPs) specific for TcdB
CPD that will permit the molecular dissection of its unique allo-
steric activation mechanism. The information presented here
may also be valuable for the study of protease domains in other
bacterial toxins.
RESULTS
Inhibitor Design and Screening
The use of peptide-based inhibitors is an effective strategy for
selectively inactivating proteases through mimicry of natural
substrates (Berger et al., 2006; Kato et al., 2005; Powers et al.,1202 Chemistry & Biology 17, 1201–1211, November 24, 2010 ª20102002). Given the importance of the CPD in regulating C. difficile
glucosylating toxin function (Egerer et al., 2007; Reineke et al.,
2007), we sought to identify inhibitors of the TcdBCPD protease.
We first tested whether inhibitors specific for a related CPD
found in V. cholerae MARTX (MARTXVc) toxin (Shen et al.,
2009) could also inhibit TcdB CPD function (Figure 1). These
inhibitors contain tripeptide sequences coupled to either an
aza-epoxide or acyloxymethyl ketone (AOMK)-reactive electro-
phile (Figure 1A; see Figure S1 available online). Inhibitor potency
against TcdBCPDwas determined using a gel-based autocleav-
age assay, in which inhibitor concentration was varied in the
presence of the activator InsP6. The autocleavage substrate
TcdB(1-804) used in this assay consists of TcdB’s N-terminal
804 amino acids and contains the glucosyltransferase and
CPDs and the natural autoprocessing site. The aza-epoxide
MARTXVc CPD inhibitors were only weakly inhibitory, with both
Cbz-LLaL-EP and the related Cbz-EAaL-EP exhibiting observed
IC50’s greater than 100 mM (Figure 1B). In contrast the Cbz-EAL-
AOMK inhibitor was significantly more potent, exhibiting an
observed IC50 of 7.2 ± 0.7 mM. Because the primary difference
between the Cbz-EAaL-EP and Cbz-EAL-AOMK inhibitors is
the electrophilic reactive group, we reasoned that the AOMK
electrophile is more optimal for TcdB CPD inhibition. Therefore,
we synthesized a focused library of covalent AOMK inhibitors
based on the natural substrate cleavage sequence of the
C. difficile TcdB CPD (Figure 2A). These inhibitors consist ofElsevier Ltd All rights reserved
Figure 2. TcdB CPD Rational Inhibitor
Design and Screening
(A) Conserved substrate autocleavage site of
C. difficile TcdB and related bacterial toxins. The
toxin CPD cleaves after the highlighted leucine
residue.
(B) Focused screen of capped di- and tripeptide
covalent TcdB CPD inhibitors. Observed IC50
values were determined using the autocleavage
assay for covalent AOMK inhibitors with diverse
P2 (left) and P3 (right) residues. These compounds
were N terminally capped with Cbz, Ac, or Hpa
groups. The dipeptide inhibitor Hpa-SL-AOMK
was found to be the most potent compound.
Data represent the mean of three experiments
± standard deviation. See also Figure S1.
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Inhibitors of Clostridium difficile toxin TcdBdipeptide or tripeptide sequences coupled to the dimethylben-
zoic acid AOMK, an electrophilic group that has been described
as optimal for targeting the structurally related clan CD prote-
ases, the caspases (Kato et al., 2005; Thornberry et al., 1994).
For all inhibitors the P1 position (the residue N terminal to the
scissile bond) was held constant as leucine because this is the
primary substrate specificity determinant of bacterial CPDs
(Egerer et al., 2007; Prochazkova et al., 2009; Shen et al.,
2009). The P2 and P3 positions, as well as the N-terminal
capping group, were varied in the library.
TcdB CPD Inhibitor SAR Profile
We first probed TcdB CPD P2 specificity using a diverse set of
carboxybenzyl (Cbz)-capped dipeptide compounds (Figure 2B).
Acidic and branched aliphatic amino acids were poorly tolerated
in the P2 position, with calculated IC50’s for Cbz-EL-AOMK and
Cbz-LL-AOMK of 30 and 100 mM, respectively. Inhibitors con-
taining smaller residues such as alanine and serine were more
potent, with IC50’s for Cbz-AL-AOMK and Cbz-SL-AOMK of
1.64 ± 0.08 mM and 1.55 ± 0.26 mM, respectively. Unexpectedly,
compounds with basic residues in the P2 position were also
potent, with an IC50 of 1.06 ± 0.07 mM observed for Cbz-KL-
AOMK. We examined whether the enhanced potency of Cbz-
KL-AOMK was specific to this residue or whether other amino
acids with a positive charge could recapitulate this effect.
Consistent with the latter interpretation, compounds with argi-
nine and ornithine in the P2 position were also potent inhibitors
(Figure 2B).Chemistry & Biology 17, 1201–1211, November 24, 2010 ªWe next assessed the contribution of
the Cbz cap to inhibitor recognition by
synthesizing acetyl (Ac) and hydroxy-
phenyl acetyl (Hpa)-capped analogs of
Cbz-KL-AOMK and Cbz-SL-AOMK.
Although the smaller Ac group
decreased potency compared to the
Cbz cap for both compounds, the Hpa
cap increased potency, resulting in an
observed IC50 of 0.71 ± 0.05 mM for
Hpa-SL-AOMK (Figure 2B). These results
indicate that hydrophobic bulk in the
dipeptide cap/ P3 binding position
contributes to TcdB CPD inhibitorpotency. Notably, the most potent compound (Hpa-SL-AOMK)
contains amino acids found in the natural TcdB CPD substrate
(Figure 2A).
Based on these results, we surveyed the P3 specificity of the
protease domain using the same technique. We synthesized
a focused library of Ac-capped tripeptide AOMK inhibitors con-
taining the natural leucine and serine residues fixed in the P1 and
P2 positions, respectively. The P3 position was varied using
a diverse set of amino acids (Figure 2B). Additionally, given the
favorable contribution of aromatic bulk in the dipeptide cap
site, three nonnatural amino acids with an aromatic side chain
were included in the P3 position (Figure 2; Figure S1B). Ac-cap-
ped tripeptide inhibitors containing small or basic residues in the
P3 position were the most potent, whereas an acidic residue in
the P3 positionwas poorly tolerated (Ac-ESL-AOMK) (Figure 2B).
More diversity was tolerated in the P3 position of inhibitors con-
taining the natural SL cleavage sequence in the P2/P1 positions.
Bulky residues such as leucine were tolerated, with an IC50 of
4.95 ± 0.37 mM observed for Ac-LSL-AOMK. Homophenylala-
nine (hPhe) was the most potent of the inhibitors containing
aromatic P3 residues, with an observed IC50 of 3.32 ±
0.26 mM. This is possibly because its methylene extension at
the b-carbon position affords more flexibility in assuming
productive interactions with the protease domain (Figure S1B).
Conversely, aromatic bulk in the P4 position decreased inhibitor
potency because the Cbz-capped GSL-AOMK inhibitor was
3-fold less potent than the analogous inhibitor carrying the
smaller Ac cap (4.46 ± 0.47 mMversus 1.78 ± 0.16 mM). However,2010 Elsevier Ltd All rights reserved 1203
Table 1. Data Collection and Refinement Statistics for the TcdB
CPD in Complex with InsP6 and Ac-GSL-AOMK
TcdB CPD + Ac-GSL-AOMK
Data collection
Space group C 2
Cell dimensions
a, b, c (A˚) 128.3, 45.5, 87.2
a, b, g () 90, 103.5, 90
Wavelength (A˚) 1.0
Resolution (A˚) 50–2.0 (2.11–2.0)
Rmerge 0.116 (0.534)
I / sI 9.2 (2.9)
Completeness (%) 100.0 (100.0)
Redundancy 6.7 (5.8)
Refinement
Resolution (A˚) 50.0–2.0
Number of reflections (total/test) 31,654/1,692
Rwork/Rfree 18.8/23.3
Number of atoms
Protein 3,886
InsP6 72
Calcium 1
Sodium 2
Inhibitor 44
Water 286
B factors
Protein 34.6
InsP6 29.1
Calcium 29.0
Sodium 34.8
Inhibitor 43.4
Water 41.0
Rmsd
Bond lengths (A˚) 0.010
Bond angles () 1.304
Highest resolution shell is in parentheses.
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Inhibitors of Clostridium difficile toxin TcdBnone of the compounds in the P3 library was more potent than
the most potent dipeptide inhibitor, Hpa-SL-AOMK.Crystal Structure of Inhibitor-Bound TcdB CPD
In order to rationalize the results of the SAR analyses and to gain
structural insight into substrate recognition by TcdB CPD, we
co-crystallized and solved the structure of InsP6-bound CPD
covalently inhibited with the Ac-GSL-AOMK inhibitor at 2.0 A˚
(Table 1). Although this inhibitor was not the most potent
compound identified in the screen, it reflects the natural
substrate cleavage site and exhibited improved solubility over
dipeptide compounds carrying aromatic caps. The overall
structure of inhibitor-bound, activated TcdB CPD (Figures 3A
and 3B) is similar to the previously solved InsP6-bound structure
of TcdA CPD, which shares 60% identity with TcdB CPD
(rsmd of 1 A˚) (Pruitt et al., 2009).1204 Chemistry & Biology 17, 1201–1211, November 24, 2010 ª2010As with most proteases, the substrate-binding pocket of TcdB
CPD can be subdivided into multiple subsites. The catalytic resi-
dues are positioned between the S1 and S1
0 subsites; the
numbering of the subsites reflects the corresponding substrate
residue recognized, with the prime subsites interacting with
substrate residues C terminal to the scissile bond. The most
striking feature of the inhibitor structure is the insertion of the
P1 leucine within a deep hydrophobic S1 pocket (Figure 3C).
Eight residues, seven of which are nonpolar, are within van der
Waals (4.4 A˚) bonding distance of the P1 leucine side chain.
Ile589 and Ala593 are contributed by helix 1 (Figure S2); Ile651
and Gly652 are contributed by strand D; Leu696 and Gly697
are contributed by strand E; and Val744 is contributed by strand
G1 of the b-flap, a functional region that is involved in both InsP6
recognition and substrate binding (Lupardus et al., 2008; Pro-
chazkova et al., 2009; Pruitt et al., 2009). Ile746 from the G1
strand of the b-flap forms the distal side of the P1 pocket
away from the active site, yet falls just outside van der Waals
bonding distance in our structure. It likely also contributes to
P1 recognition in vivo because the inhibitor may be pulled in
slightly toward the catalytic cysteine due to the covalent nature
of the modification. Because most of these residues are also
conserved in the related MARTXVc CPD, which binds to and
cleaves after a P1 leucine (Prochazkova et al., 2009; Shen
et al., 2009), bacterial CPDs would appear to share a common
mechanism for recognition of this primary substrate specificity
determinant.
Whereas many residues in the S1 subsite participate in recog-
nition of the P1 Leu, residues in the other subsites make minimal
interactions with the inhibitor (Figure 3C). In the S2 subsite the
main chain carbonyl of Val744 forms a hydrogen bond with the
P2 serine backbone amide of the inhibitor, whereas on the prime
side themain chains of Gly654 andCys698, which form the ‘‘oxy-
anion hole,’’ hydrogen bondwith the carbonyl formed after inhib-
itor reaction (Figure 3C). The P2 serine side chain points toward
Glu743; in contrast the P3 glycine is oriented such that the P3
side chain would be exposed to solvent. Thus, the inhibitor struc-
ture of TcdB CPD reveals the mechanistic basis for substrate
recognition.
Inhibitor Docking Findings
To gain additional insight into the inhibitor-specificity require-
ments of the active site, we used docking simulations to replace
the Ac-GSL-AOMK in the TcdB CPD crystal structure with other
compounds from the focused library. The structure of the
modeled inhibitor and all side chains within 4.5 A˚ were energy
minimized using the default parameter of the Molecular Oper-
ating Environment (MOE) software. The docking simulations
suggest an explanation for why compounds containing basic
amino acids such as lysine or arginine in the P2 position were
particularly potent. In these analyses the positively charged P2
residue forms an electrostatic interaction with the acidic
Glu743 residue, which helps to form the S2 pocket (Figure 4).
This negatively charged subsite likely also explains why the
Cbz-EL-AOMK was not as potent because this inhibitor cannot
form the same favorable electrostatic interactions during binding
(Figure 4). Instead, the acidic glutamate of the inhibitor is pre-
dicted to interact with Arg745; however, this interaction may
be unfavorable given that Arg745 likely stabilizes the activatedElsevier Ltd All rights reserved
Figure 3. Structure of Activated TcdB CPD Bound to Ac-GSL-AOMK Inhibitor
(A) Ribbon structure of TcdB CPD in complex with InsP6 viewed from above the InsP6 binding site. InsP6 is shown as a stick model.
(B) A view of the structure rotated 120 to show inhibitor bound in the active site. InsP6 and the inhibitor are shown as stick models. The b-flap hairpin that
separates the InsP6 binding and active sites is indicated.
(C) Close-up view of the substrate-binding pocket. Hydrophobic residues in the S1-binding pocket are shown as orange sticks, and the inhibitor is shown as
yellow sticks. Side chains that interact with the P1 leucine are shown; hydrogen bonds are indicated by dotted lines. See also Figure S2.
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Inhibitors of Clostridium difficile toxin TcdBconformation of the CPD through a p-cation interaction with the
highly conserved Trp761 (Pruitt et al., 2009).
The docking studies also rationalize the increased potency of
the dipeptide inhibitors capped with bulky Cbz or Hpa groups.
These caps are predicted to fit into a hydrophobic groove formed
between Ile746 and Ile589 such that the hydroxyl of the Hpa cap
serves as the donor in a hydrogen bond with Ile746 (Figure 4).
This may help favorably orient the inhibitors during binding and
subsequent reaction with the catalytic Cys698.
TcdB CPD Inhibitor Blocks Full-Length Toxin Function
In order to determine if the inhibitors identified in vitro were
functional in cells, we assessed their ability to block the intox-
ication of primary human foreskin fibroblasts (HFFs) by TcdB
holotoxin. Pretreating cells with the most potent inhibitors pre-
vented the cytopathic effects induced by recombinant TcdB
holotoxin (Figure 5A). Cell rounding was quantified for select
compounds by counting the number of rounded cells visible
per field upon inhibitor titration (Figure 5B). The results corrob-
orate the potency rankings observed in the initial autocleavage
screen. Two of the most potent compounds, Hpa-SL-AOMK
and Hpa-KL-AOMK, prevented cell rounding. Hpa-SL-AOMK
completely inhibited toxin function by 100 mM, with an
observed IC50 of approximately 20 mM, whereas the Hpa-KL-
AOMK was slightly less potent. The difference in potency
between Hpa-SL-AOMK and Hpa-KL-AOMK may be due to
the increased cell permeability of the P2 serine relative to the
positively charged lysine. Cell permeability of the inhibitors is
likely to determine their potency because CPD inhibition can
only occur after toxin entry into cells, when the CPD can
become activated by InsP6. In contrast the negative controls
Cbz-EL-AOMK and the epoxide-based pan-cathepsin inhibitor
JPM-OEt (Bogyo et al., 2000; Greenbaum et al., 2000) both
failed to inhibit toxin function just as they poorly inhibit CPD
activity (Figure 2B; Figure S1). Surprisingly, Cbz-KL-AOMK
and to a lesser extent Cbz-SL-AOMK were found to be cyto-Chemistry & Biology 17, 1201–121toxic (Figure S3). Given that no toxicity was observed for the
Hpa-capped analogs, these findings implicate the Cbz cap in
affecting cell viability.
We confirmed that inhibition of the TcdB CPD directly pre-
vented holotoxin effector domain activity by monitoring glucosy-
lation of its cellular target Rac1, a Rho GTPase (Genth et al.,
2006; Yang et al., 2008). Addition of wild-type toxin to cells re-
sulted in complete glucosylation of Rac1, whereas pretreatment
with either Hpa-SL-AOMK or Hpa-KL-AOMK was protective
(Figure 5C). Importantly, inhibition of cathepsins using JPM-
OEt had no effect on toxin function; JPM-OEt was used as
a control because P1 Leu AOMKs have previously been shown
to weakly cross-react with the cathepsins (Kato et al., 2005).
Probe Design to Monitor Toxin Activation
The activation of the CPD by the eukaryotic-specific small mole-
cule InsP6 is a critical step in regulating the function and traf-
ficking of C. difficile glucosylating toxins (Egerer and Satchell,
2010; Shen, 2010). In order to facilitate more detailed studies
of this important process, we created fluorescently tagged
and biotin-tagged probe versions of the SL-AOMK inhibitor
(AWP19 and AWP15, respectively) to visualize toxin activation
(Figure 6A). Both AWP19 and AWP15 covalently label the recom-
binantly produced TcdB(1-804) autocleavage substrate in
response to small molecule activation of the protease by InsP6
(Figure 6B). This substrate represents the toxin region predicted
to translocate into the cytosol during intoxication. Notably, the
cleavage product TcdB(544-804) formed after proteolytic
cleavage was more active than the full-length substrate, as
shown by the increase in ABP labeling relative to the amount
of protein present (Figures 6B and 6C). This observation
suggests that the isolated CPD TcdB(544-804) is either more
accessible or more reactive with the probe than the full-length
substrate. As expected, the ABPs failed to label the catalytically
inactive C698A mutant of TcdB(1-804) in the presence or
absence of InsP6.1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1205
Figure 4. Molecular-Docking Analyses of
TcdB CPD with AOMK Inhibitors
Close-up view of the substrate-binding pocket
shown with electrostatic surface potential. Blue
denotes positively charged surface; red denotes
negatively charged surface. Inhibitors are shown
as yellow sticks, and relevant residues are indi-
cated. The Ac-GSL-AOMK image is derived from
thecrystal structureof the inhibitor-boundenzyme.
Binding of the Cbz-EL-AOMK is predicted to bind
TcdB CPD differently from the other inhibitors.
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combinant holotoxin, which was either produced in E. coli or in
the Bacillus megaterium expression system (Pruitt et al., 2010;
Yang et al., 2008) (Figure 6C). The B. megaterium system
produces a His6-tagged TcdB holotoxin that is more pure than
the native toxin purified from C. difficile culture supernatants
(Genth et al., 2006; Yang et al., 2008). Both probes could sensi-
tively detect active CPD within the toxin because the cleaved
TcdB(544-2366)-His6 fragment could be labeled by the probe
even though it is not detectable by either Coomassie or anti-
His6 antibody-conjugated horseradish peroxidase. Titration of
probe labeling confirmed the potency of the probes, with
AWP19 labeling active holotoxin at probe concentrations below
50 nM (Figure S4). This level of sensitivity will be valuable for
tracking CPD activation during toxin trafficking because it
permits the labeling of ensembles of toxin while minimizing the
risk of completely inhibiting toxin function.
Monitoring toxin trafficking is further enabled by the cell perme-
ability of AWP19’s near-infrared fluorescent cyanine 5 tag, which
allows the probe to be used in intact cells. In order to check for
off-targets of this probe, we incubated both primary HFFs and
the RAW macrophage cell line with AWP19. In both cell types
the only off-target the probe labeled was cathepsin B, as1206 Chemistry & Biology 17, 1201–1211, November 24, 2010 ª2010 Elsevier Ltd All rights reconfirmed by comparison with a pan-
cathepsin ABP (Figure S5) (M.G. Paulick
and M.B., unpublished data). Similarly,
pretreatment of both cell types with Cbz-
SL-AOMK prevented cathepsin B labeling
by the pan-cathepsin probe, but not
cathepsin L or X labeling. Thus, cathepsin
Bwouldappear tobe theprimaryoff-target
TcdB CPD inhibitors. Nevertheless,
cathepsin B inhibition was not sufficient
to reduce TcdB toxin function because
the pan-cathepsin inhibitor JPM had no
effect on toxin-induced cell rounding or
Rac1 glucosylation (Figure 5). This result
strongly suggests that the observed
reduction in TcdB-glucosylating activity in
targetcells upon treatmentwithCPD inhib-
itors is due to inhibition of CPD function.
DISCUSSION
The rising rate of C. difficile infections
necessitates the development of newclasses of therapeutics to combat this pathogen. Because of
its natural antibiotic resistance, there has been increased focus
on targeting the glucosylating toxins TcdA and TcdB for direct
therapeutic intervention because they are the primary media-
tors of C. difficile pathogenesis (Halsey, 2008; Kelly and
LaMont, 2008; Rupnik et al., 2009). In this study, to our knowl-
edge, we present the first validation that the TcdB CPD is
a druggable target. Although inhibition of this protease active
site is difficult because the small molecule is competing with
an intramolecular autoproteolytic event, our findings are
encouraging for the development of competitive inhibitors for
the TcdB CPD. The most potent compound in our library is
the 499 Da-capped dipeptide inhibitor Hpa-SL-AOMK (Figure 2),
which is within the size constraints generally accepted for
therapeutics (Lipinski, 2000). In addition the minimal interaction
between the protease and inhibitor peptide backbone (Figure 4)
suggests that inhibitors with non-peptidic scaffolds can be
developed to bypass the pharmacokinetic shortfalls of peptidic
compounds.
Our rational approach to probing the inhibitor sensitivity of the
CPD active site using structural analysis and a focused library of
substrate-based compounds yielded multiple inhibitors capable
of blocking holotoxin function (Figure 5). These analysesserved
Figure 5. TcdB CPD Inhibitors Block Holotoxin Function
(A) Primary HFFs pretreated with Hpa-SL-AOMK are protected from holotoxin-mediated cell rounding. HFFs treated with the catalytically inactivated C698A hol-
otoxin or left untreated exhibit minimal cell rounding.
(B) Quantification of inhibitor effects on holotoxin-mediatedHFF cell rounding. Pretreatment with Hpa-SL-AOMKor Hpa-KL-AOMKwas protective, whereasCbz-
EL-AOMK and the pan-cathepsin inhibitor JPM-OEt had no effect on toxin function. Data represent the mean of three experiments ± standard deviation.
(C) Addition of wild-type TcdB holotoxin to HFFs results in complete glucosylation of the Rho GTPase Rac1, as seen by western blot with the glucosylation-sensi-
tive a-Rac1 monoclonal antibody mAb102. Pretreating the cells with Hpa-SL-AOMK or Hpa-KL-AOMK protected HFFs from toxin effector domain activity,
whereas inhibiting cathepsin activity with JPM-OEt did not. See also Figure S3.
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basic P2 or P3 residues and bulky hydrophobic N-terminal caps
could potently block TcdB autoprocessing. This SAR profile
provides a starting point for the development of compounds suit-
able for therapeutic applications. We note that relying solely on
substrate-specificity profiling for these domains may not have
produced such promising results because potent substrates
do not always translate into viable inhibitors (Drag et al., 2010).
Furthermore, fluorogenic substrate cleavage assays lack sensi-
tivity in detecting bacterial CPD activity because these autopro-
cessing enzymes exhibit poor transcleavage efficiency (Babe
and Craik, 1997; Lupardus et al., 2008). Our attempts to develop
optimized substrates for TcdB CPD produced substrates with
poor Km values (1 mM; data not shown). The approach
described here may also prove applicable to other protease
domain-containing bacterial toxins (Lebrun et al., 2009).
Information about the inhibitor sensitivity profile of TcdB CPD
was bolstered by our crystal structure of the enzyme bound to
the Ac-GSL-AOMK inhibitor (Figure 3). This structure permitted
the molecular-docking studies that helped rationalize the
increased potency of inhibitors with basic P2 residues and bulky
hydrophobic N-terminal caps (Figure 4). Furthermore, given the
overall similarity between the inhibitor structure of InsP6-bound
TcdB CPD presented here and InsP6-bound TcdA CPD (Pruitt
et al., 2009), many of our findings may be translatable to inhibit-
ing this closely related toxin. Our most efficacious inhibitor Hpa-
SL-AOMK will likely exhibit similar potency against TcdA due to
its identical P1/P2 substrate sequence (Figure 2A), increasing its
value as a C. difficile virulence-targeting agent.Chemistry & Biology 17, 1201–121This crystal structure also permits comparisons to be made
with the inhibitor-bound structure of the related CPD of Vibrio
cholerae MARTX toxin (Shen et al., 2009). Both inhibitor struc-
tures reveal that the primary substrate specificity determinant
for these proteases is the P1 leucine, and residues involved in
recognizing this leucine are conserved in both proteases. The
inhibitor structures differ in that MARTXVc CPD makes more
backbone interactions with its inhibitor than TcdB CPD and in
the S10 subsite, the region that recognizes residues C terminal
to the scissile bond. For MARTXVc CPD this region is relatively
flat and featureless, whereas in TcdB CPD, Asp656 and
Glu657 directly extend into this region and may thus occlude
substrate or inhibitor binding (Figure S6). This acidic extension
may explain why such a large difference in potency was
observed between the Cbz-EAL aza-epoxide and AOMK deriva-
tives for TcdB CPD (Figure 1), whereas both warheads inhibit
MARTXVc CPD to a similar extent (Shen et al., 2009).
The CPDs of both the C. difficile large glucosylating and
MARTX toxin families appear to ‘‘sense’’ the eukaryotic cell envi-
ronment and activate toxin function accordingly (Egerer and
Satchell, 2010; Shen, 2010). However, this unique allosteric acti-
vation process is difficult to study using traditional biochemical
approaches because it is posttranslationally regulated. Our
ABPs overcome this problem because they afford the direct
visualization of CPD activation by InsP6 in complex mixtures
and possibly in vivo. Furthermore, the probes provide a robust
readout for CPD activity that could be used in screening applica-
tions for competitive (Schneider and Craik, 2009) or allosteric
inhibitors (Lee and Craik, 2009) of the CPD, in lieu of fluorogenic1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1207
Figure 6. Probe Labeling of Recombinant TcdB
(A) Structures of Cy5-labeled AWP19 and biotin-labeled AWP15 TcdB CPD probes.
(B) Labeling of either wild-type or catalyticmutant C698A TcdB(1-804) (0.5 mM) by probes (10 mM) in the presence (25 mM, +) or absence () of InsP6. Fluorescence
scanning was used to detect AWP19 labeling, whereas streptavidin-HRP blotting was used to detect AWP15 labeling; total protein was detected by Coomassie
staining. A small fraction of cleaved TcdB544-804 is detectably labeled by both probes even though it is not detectable by Coomassie staining.
(C) Labeling of holotoxin produced in E. coli (wild-type and catalytic mutant C698A) and Bacillus megaterium by probes (10 mM) in the presence (25 mM, +) or
absence () of InsP6. The amount of protein loaded is indicated. ‘‘Pre’’ refers to B. megaterium-produced holotoxin that was pretreated with 25 mM InsP6 (to
induce autoprocessing) for 1 hr at 37C prior to labeling, after which 10 mM of probe was added to the sample. Fluorescence scanning was used to detect
AWP19 labeling, whereas streptavidin-HRP blotting was used to detect AWP15 labeling. Total protein was visualized using Coomassie staining, whereas
His6-tagged holotoxin was visualized using anti-His antibody western blotting. See also Figures S4 and S5.
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Inhibitors of Clostridium difficile toxin TcdBsubstrates (which react poorly with the protease) or autocleav-
age assays (which are less sensitive).
Because of the covalent nature of these probes, they provide
a direct readout of when the toxin has encountered InsP6. This is
valuable within the context of studies directed at dissecting toxin
trafficking and the molecular mechanisms underlying the allo-1208 Chemistry & Biology 17, 1201–1211, November 24, 2010 ª2010steric regulation of toxin function by InsP6 (Giesemann et al.,
2008; Jank and Aktories, 2008). For example it is notable that
the cleaved form of TcdB CPD is more effectively labeled by
the ABP than the full-length protein (Figure 6). This may imply
that the CPD is held in an inhibitory conformation within the
native holotoxin and that autoproteolytic cleavage relieves thisElsevier Ltd All rights reserved
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the ABP following cleavage, which would suggest that the
conformation of full-length TcdB in vitro occludes substrate
binding. C. difficile-glucosylating toxins undergo significant
conformational rearrangements during the pH-dependent toxin
translocation process (Pruitt et al., 2010; Qa’Dan et al., 2000).
Based on our observation that cleaved TcdB toxin (aa 544-
2366) was alsomore readily labeled by the probe in the presence
of InsP6 (Figure 6C), it is tempting to speculate that the CPD is
subject to additional regulation at the level of toxin conformation.
Further studies using these promising tools will provide a more
detailed understanding of the regulation of the CPD by InsP6
and in the context of the full-length toxin.
SIGNIFICANCE
The large glucosylating toxins TcdA and TcdB are the
primary virulence factors of the antibiotic-resistant bacte-
rium Clostridium difficile. These toxins are autoproteolyti-
cally activated by an internal cysteine protease domain
(CPD) in a step that is critical for toxin function. We synthe-
sized a focused library of substrate-based compounds in
order to determine a structure-activity relationship for
TcdB CPD inhibitors and then gained further insight by co-
crystallizing the domain with one of these inhibitors. This
rational approach yielded compounds potent enough to
inhibit toxin function in cell culture, validating the clos-
tridial-glucosylating toxins as druggable targets. Our results
provide a promising starting point for the development of
therapeutics that minimize the selective pressure onC. diffi-
cile to develop resistance. We also used the inhibitor data to
develop covalent activity-based probes (ABPs) that can
directly measure the allosteric activation of the protease
by the small molecule inositol hexakisphosphate. Because
these ABPs monitor the posttranslational activation of the
toxin, theywill be useful in studies directed at understanding
this unique regulatory mechanism in both biochemical and
cell-based assays.
EXPERIMENTAL PROCEDURES
Compound Synthesis
The aza-leu epoxide inhibitors were synthesized in solution using standard
chemistry as previously described (Asgian et al., 2002). The AOMK inhibitors
were synthesized using solid-phase synthesis as previously described (Kato
et al., 2005). The ABP AWP19 was synthesized by combining H2N-aminohex-
anoic-SL-AOMK (1 equivalent) with Cy5-NHS (0.9 equivalents) and DIEA (5
equivalents) in DMSO for 1 hr and then purifying directly by HPLC. The identity
and purity of all compounds were characterized using HR-MS and LCMS.
Protein Expression and Purification
An overnight culture of pET28a-TcdB1-804 was diluted 1:500 into 4 L 2YTmedia
and grown shaking at 37C.When an OD600 of 0.6–0.9 was reached, IPTGwas
added to 250 mM, and cultures were grown for 3 hr at 225 rpm at 30C.
Cultures were pelleted, resuspended in 60 ml lysis buffer (500 mM NaCl,
50 mM Tris-HCl [pH 7.5], 15 mM imidazole, and 10% glycerol) and flash frozen
in liquid nitrogen. Lysates were thawed, then lysed by sonication and cleared
by centrifugation at 15,000 3 g for 30 min. C-terminally His6-tagged TcdB(1-
804) was affinity purified by incubating the lysates in batch with 2.0 ml Ni-NTA
Agarose beads (QIAGEN) with shaking for 3 hr at 4C. The binding reaction
was pelleted at 1500 3 g, and the pelleted Ni-NTA agarose beads were
washed three times with lysis buffer. His6-tagged CPD was eluted from theChemistry & Biology 17, 1201–121beads by the addition of 400 ml high imidazole elution buffer (500 mM NaCl,
50 mM Tris-HCl [pH 7.5], 175 mM imidazole, and 10% glycerol). The elution
was repeated three times; the eluate was pooled, buffer exchanged in gel-
filtration buffer (200 mM NaCl, 10 mM Tris [pH 7.5], and 5% glycerol), and
concentrated to 750 ml. The concentrated prep was pelleted at 13,000 3 g
for 10 min at 4C prior to loading on a HiPrep S200 16/60 Sephacryl column
(GE Healthcare). Purified His6-tagged CPD was concentrated and stored at
20C in gel-filtration buffer.
TcdB Autocleavage Assay
Recombinant TcdB(1-804) was diluted to a final concentration of 0.5 mM in
assay buffer (60 mM NaCl, 20 mM Tris [pH 7.5], and 250 mM sucrose) in
a 96 well plate. A total of 0.5 ml of a 1003 inhibitor stock in DMSO was then
added to each well in triplicate, and the samples were incubated at 37C for
30 min. InsP6 (0.5 ml, Calbiochem) was then added to a final concentration
of 25 mM, and the reaction was incubated at 37C for 1 hr. Samples were
then diluted in 43 SDS-PAGE loading buffer and resolved by SDS-PAGE on
12% gels. Cleavage reactions were visualized by Coomassie staining and
quantified using the program ImageJ (http://rsb.info.nih.gov/ij/). For each
sample the amount of autocleaved protein relative to the total protein amount
was plotted versus the concentration of inhibitor and globally fit using the
sigmoidal function in KaleidaGraph.
Protein Purification, Crystallization, and Data Collection
An overnight culture of pET22b-TcdB544-797 was diluted 1:500 into 3 liters of
2YT media and grown shaking at 37C. When an OD600 of 0.6–0.9 was
reached, IPTG was added to 250 mM, and cultures were grown for 12–16 hr
(225 rpm) at 18C–20C. Cultures were pelleted, resuspended in 50 ml lysis
buffer (500 mM NaCl, 50 mM Tris-HCl [pH 7.5], 15 mM imidazole, and 10%
glycerol), and flash frozen in liquid nitrogen. Lysates were thawed, then
lysed by sonication and cleared by centrifugation at 15,000 3 g for 30 min.
TcdB544-797 was purified as described above except that it was concentrated
to 1 mM, and the gel-filtration buffer was 150 mM NaCl, 10 mM Tris (pH 7.5).
Gel-filtration purified TcdB(544-797) was treated with 2 mM InsP6 and 2 mM
Ac-GSL-AOMK (inhibitor stock was at 200 mM in DMSO). The inhibitor was
added slowly due to poor solubility; reaction with the protease improved inhib-
itor solubility. The reaction was allowed to proceed for 1 hr at room tempera-
ture after which excess inhibitor was pelleted by centrifuging the reaction at
13,000 3 g for 10 min at 4C. Crystallization screening was carried out using
the sitting drop vapor-diffusion method, and initial hits were observed in
0.1 M Tris HCl (pH 8.0) and 30% PEG2000 MME as the precipitant. Crystals
used for data collection were grown in 1 ml drops by mixing equal volumes
of protein with mother liquor and appeared only after 45–60 days. Crystals
were cryoprotected in 45% PEG2000 MME, flash frozen in liquid nitrogen,
and data collected under cryo-cooled conditions at 100 K at beamline 8.2.1
at the Advanced Light Source (University of California-Berkeley). Diffraction
data were processed using MOSFLM (Leslie, 1991) and SCALA (Potterton
et al., 2003), and processing statistics are listed in Table 1.
Structure Determination and Refinement
Initial phases were obtained by molecular replacement with PHASER (McCoy
et al., 2007) using the structure of the TcdA CPD (PDB ID 3HO6) as a search
model (Pruitt et al., 2009). Using the molecular replacement phases, the
TcdB CPD was built by ARP/wARP (Perrakis et al., 1999) to approximately
85% completeness, followed by rounds of model building and adjustment
with COOT (Emsley and Cowtan, 2004) and refinement with PHENIX (Adams
et al., 2002). Restraints for the Ac-GSL molecule were obtained from the
PRODRG server (Schuttelkopf and van Aalten, 2004). The final model under-
went restrained and translation/libration/screw refinement in REFMAC5 (Mur-
shudov et al., 1997), resulting in final R/Rfree values of 18.8% and 23.3%.
Ramachandran analysis of model geometry by MolProbity (http://molprobity.
biochem.duke.edu/) indicates that 99.0% of residues reside in the most favor-
able regions, with none in the disallowed regions. Refinement statistics can be
found in Table 1. Structural figures were preparedwith PyMOL (DeLano, 2002).
The final model contains two TcdB CPD molecules in the asymmetric unit
(ASU), with each bound to one InsP6molecule, one Ac-GSL inhibitor molecule,
two sodium ions, and a calcium ion bridging the crystal contact between the1, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1209
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paper.
Docking Simulations
The different homology models of TcdB CPD were built from the crystal struc-
ture of the protease bound of Ac-GSL-AOMK using the default parameters of
the MOE software. In eachmodel the covalent linkage to Cys698 and the posi-
tion of leucine in the P1 pocket were initially fixed as those of the crystal struc-
ture. The N-terminal cap and P2 side chain were manually built into the active
site of the protease. Energy minimization was performed first on the modified
region of the inhibitor and all side chains within 4.5 A˚, and second on the entire
inhibitor and all side chains within 4.5 A˚.
Cell Rounding Assay
Primary HFFs were seeded in 96 well plates at a density of 1–23 104 cells/well
in DMEM supplemented with 10% FBS. Prior to the assay the cells were
washed three times with 100 ml DMEM alone. Onemicroliter of a 1003 inhibitor
stock in DMSO was then added to each well in triplicate, and the cells were
incubated at 37C for 30 min. Recombinant TcdB holotoxin expressed in
E. coli was then added to the cells at a final concentration of 0.3 pM. The
samples were incubated at 37C for 2 hr and then imaged using a 203 objec-
tive on an inverted microscope. Four fields were imaged per well, and the
average number of rounded cells per field was calculated.
Rac1 Glucosylation Assay
HFF cells were seeded into 24 well treated plates (7.5 3 105) and grown to
100% confluency overnight, washed once with pre-warmed DMEM, and left
in 0.25 ml DMEM per well. The indicated concentration of inhibitor was added
as a 1:100 dilution from a DMSO stock and incubated for 30min. Recombinant
TcdB holotoxin purified from E. coli was added to the cells (0.3 pM) and incu-
bated for 90 min at 37C. The media were removed and then the cells were
lysed in 25 ml 13 FSB by scraping the cells in concentric circles. Cell lysates
were boiled for 5 min at 95C, and 15 ml of lysate was resolved on a 14%
SDS-PAGE gel and transferred to nitrocellulose. Unglucosylated Rac1was de-
tected using a 1:1000 dilution of mAb102 (Millipore) and a 1:5000 dilution of
anti-mouse IgG HRP (BioRad). Actin was simultaneously visualized using
a polyclonal anti-actin antibody at 1:2000 dilution (Sigma), and a 1:5000 dilu-
tion of anti-rabbit IgG HRP (BioRad).
Purification of TcdB Holotoxin from E. coli
Overnight cultures of pET28a-TcdB wild-type or C698A holotoxin were diluted
1:500 into 3 liters of 2YT media and grown shaking at 37C. C-terminally His6-
tagged holotoxin was purified as described for His6-tagged TcdB(1-804) with
the exception that b-mercaptoethanol was added to the lysis buffer at 2 mM.
AWP19 and AWP15 Labeling of Recombinant TcdB(1-804)
Wild-type and C698A TcdB 1-804 (0.5 mM) were incubated with 10 mM of the
indicated probe. InsP6 was added to a final concentration of 25 mM (1:100 dilu-
tion) in a total volume of 50 ml where indicated, and probe labeling proceeded
for 1 hr at 37C. Fifteen microliters of 43 final sample buffer were added and
then the sample was boiled for 3 min at 95C. The samples were resolved on
a 10% gel by SDS-PAGE. For AWP19 labeling, fluorescent labeling was visu-
alized using a fluorescent scanner followed by Coomassie staining. For
AWP15 staining the sample was loaded in duplicate, and one set was visual-
ized by Coomassie staining (5 ml sample loaded), whereas the other set was
transferred to nitrocellulose (2.5 ml sample loaded) and blotted using strepta-
vidin-HRP (Sigma) at 1:3000.
AWP19 and AWP15 Labeling of Recombinant TcdB
For labeling of TcdB holotoxin purified from E. coli, wild-type and C698A TcdB
was diluted to 0.3 mM in assay buffer and then the indicated probe was added
to 10 mM (1:100 dilution from DMSO stock) in a total volume of 15 ml. InsP6 was
added at a final concentration of 25 mM where indicated. For labeling of TcdB
holotoxin purified from B. megaterium (a gift from R. Pruitt and D.B. Lacy),
0.5 mMof toxin was diluted in CPDbuffer and then 10 mMof the indicated probe
was added (1:100 dilution from DMSO stock). InsP6 was then added at a final
concentration of 25 mM. Alternatively, InsP6 (25 mM) was added to the B.meg-
aterium-produced toxin (0.5 mM) and incubated for 1 hr at 37C and then the1210 Chemistry & Biology 17, 1201–1211, November 24, 2010 ª2010indicated probe was added at 10 mM final concentration. Following probe
addition, the labeling reactions were allowed to proceed for 1 hr at 37C, after
which 5 ml of 43 FSB was added, and the samples were boiled for 3 min at
95C. For AWP19 labeled samples, 15 ml was resolved on a 10% gel and
then visualized by fluorescence scanning followed by Coomassie staining.
For AWP15-labeled samples the samples (either 5 or 2.5 ml) were loaded in
duplicate and resolved on a 10% gel, then transferred to nitrocellulose. The
membranes were probed with Streptavidin-HRP (Sigma) at 1:3,000 (5 ml
sample loaded) or with an anti-His antibody (Pierce) and anti-rabbit IgG HRP
(BioRad) at 1:10,000 (2.5 ml sample loaded).
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